Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,132.00+0.56%ETH$2,513.04+2.83%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
NE

NASDAQ · NERV

Minerva Neurosciences, Inc.

Healthcare · Biotechnology

$4.16

Down-$0.01 (-0.24%)

Updated Sep 11, 2026, 10:47 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
28.95M
P/E ratio
2.79
Dividend yield
0.00%
52-week range
$1.93 – $12.46
Volume
72.1K
Avg. volume
3.01M

Price performance

NERV price history

1M range · 0 trading sessions · Daily adjusted prices

NERV does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NERV news

The latest Smart Investors Daily articles mentioning NERV.

Stock researchCompany · Overview

NERV research

Overview

Company profile and research snapshot.

Company profile

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$5.00
Implied upside
—
Analysts
—
NERV recent ratings
DateFirmRatingTarget
Aug 14, 2026JefferiesBuy—
Apr 15, 2026CitizensMarket Outperform—
Mar 12, 2026HC Wainwright & Co.Neutral—
Nov 6, 2025HC Wainwright & Co.Neutral—
Feb 26, 2025HC Wainwright & Co.Neutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 28, 2026

Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences. Wells Fargo Healthcare ConferenceDate: Tuesday, September 8Format: 1x1 meetingsLocation: New York, NY 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9Format: Fireside cha

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By